Aternalis Capital Exits Position in Impax Laboratories Inc (IPXL)

Impax Laboratories Inc (IPXL) : Aternalis Capital has sold out all of its stake in Impax Laboratories Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 130,000 shares of Impax Laboratories Inc which is valued at $2,823,600.

Other Hedge Funds, Including , Two Sigma Securities added IPXL to its portfolio by purchasing 7,346 company shares during the most recent quarter which is valued at $159,555. Impax Laboratories Inc makes up approx 0.08% of Two Sigma Securities’s portfolio.Vanguard Group Inc boosted its stake in IPXL in the latest quarter, The investment management firm added 144,892 additional shares and now holds a total of 5,605,231 shares of Impax Laboratories Inc which is valued at $121,745,617. Impax Laboratories Inc makes up approx 0.01% of Vanguard Group Inc’s portfolio.Blackrock Investment Management boosted its stake in IPXL in the latest quarter, The investment management firm added 25,698 additional shares and now holds a total of 303,791 shares of Impax Laboratories Inc which is valued at $6,598,341. Impax Laboratories Inc makes up approx 0.01% of Blackrock Investment Management’s portfolio.Tower Research Capital (trc) reduced its stake in IPXL by selling 1,597 shares or 71.42% in the most recent quarter. The Hedge Fund company now holds 639 shares of IPXL which is valued at $13,879.Acrospire Investment Management boosted its stake in IPXL in the latest quarter, The investment management firm added 2,600 additional shares and now holds a total of 3,910 shares of Impax Laboratories Inc which is valued at $119,607. Impax Laboratories Inc makes up approx 0.09% of Acrospire Investment Management’s portfolio.

Impax Laboratories Inc closed down -0.25 points or -1.03% at $23.94 with 8,38,186 shares getting traded on Thursday. Post opening the session at $24.23, the shares hit an intraday low of $23.71 and an intraday high of $24.4 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Impax Laboratories Inc reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $0.32. The company had revenue of $172.60 million for the quarter, compared to analysts expectations of $223.67 million. The company’s revenue was down -19.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.34 EPS.

Many Wall Street Analysts have commented on Impax Laboratories Inc. Impax Laboratories Inc was Upgraded by Northland Capital to ” Outperform” on Aug 15, 2016. Shares were Reiterated by WallachBeth on Aug 10, 2016 to “Buy” and Lowered the Price Target to $ 30 from a previous price target of $40 .Shares were Reiterated by Leerink Partners on Aug 10, 2016 to “Mkt Perform” and Lowered the Price Target to $ 24 from a previous price target of $33 .

Impax Laboratories Inc. is a specialty pharmaceutical company. The Company is engaged in the development manufacture and marketing of bioequivalent pharmaceutical products (generics) in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development manufacture sale and distribution of the Company’s generic products which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products indicated for the treatment of migraine headaches.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *